modified endothelial cells recruited from tumor adjacent vessels as well as from an intra-tumor vasculogenesis [3] . Concerning this possibility, renal TECs might originate from the endothelial differentiation of cancer stem cells (CSCs), a well-recognized sub-population of tumor cells able to sustain the initiation, the maintenance and the recurrence of solid tumors [3] . Of interest, it has been recently demonstrated that liver stem cell-EVs also induce apoptosis of renal CSCs, alone or in combination with drugs commonly used in clinical practice, highlighting a double, although different, effect of liver stem cell-EVs on both tumor endothelial and cancer stem cells [2, 4] .
Tumor angiogenesis might be differently modulated by stem cell-derived EVs of different origin. For instance, mesenchymal stem cell (MSC)-EVs were shown to promote tumor vascularisation in gastric and colon cancer models [5] . At variance, Lee et al. described the in vitro and in vivo inhibition of angiogenesis driven by MSCEVs through vascular endothelial growth factor downregulation in breast cancer [6] . In the paper of Lopatina et al., MSC-EVs, at variance of liver stem cell-EVs, failed to inhibit tumor angiogenesis, [2] and similar lack of activity was also reported in a recent study on murine lymphomas [7] . This variable activity of stem cell-EVs may possibly depend on the type of stem cell originating EVs as well as on their target. In this context, EVs from MSCs rather appear to display a general pro-angiogenic activity, of value for tissue regeneration. At variance, cardiac stem cell-derived EVs were able to reduce tumor vascularization in parallel with tumor proliferation, in vitro and in vivo [7] . Other reported sources of EVs with anti-tumor activity were human embryonic stem cell [8] and placental stem cells [9] .
The described effect of stem cell-EVs on tumor cells has been mainly ascribed to the transfer of specific miRNAs able to reprogram their gene expression profile (Figure 1 ). In particular, among the anti-angiogenic miRNAs identified in liver stem cell-EVs, miR-181b, miR-320c and miR-874 were described as responsible of the down-regulation of tumor angiogenic factors such as FGF1 and PLAU [2] . In addition, miR-16, enriched in MSC-EVs, was also reported to contribute to vascular endothelial growth factor down-regulation in breast cancer cells [6] and miR-146, highly enriched in cardiac stem cell-EVs, was implicated in their anti-angiogenic and anti-tumor effects [7] . Moreover, liver stem cell-EVs were shown to transfer other anti-tumor miRNAs, such as miR-451, miR-31, and miR-223 to hepatoma cells, inducing a down-regulation of their targets (MDR1, RAB14, MIF and E2F-2) [10]. As result, intracellular pathways relevant for tumor growth and survival, such as Akt/mTOR/PTEN, were down-regulated by EV treatment [4] . In addition, a synergistic activity of stem cell-EVs was observed with tyrosine kinase inhibitors, enhancing the blockade of tumor intracellular pathways in CSCs [4] .
Altogether, these data provide a rationale for the use of stem cell-derived EVs, from a number of different stem cell sources, for the treatment of solid tumors. Of interest, stem cell-derived EVs appear to act on multiple targets such as tumor endothelial cells, tumor stem cells as well as on differentiated cells (Figure 1) . Indeed, stem cell-EVs may display a unique anti-tumor effect thanks to a variety of molecular species within their cargo and to an orchestrated activity on multiple pathways.
